Prescription drug prices have been rising over the past few years.
Bristol-Myers Squibb announced Thursday that it’s going to acquire another drugmaker, Celgene. The deal is worth about $74 billion. The combined company will have nine products with sales of more than a billion dollars a year, including some blockbuster cancer drugs. The merger is a sign that Big Pharma is betting big on cancer medications. […]
The trade agreement reached over the weekend between the U.S., Canada and Mexico includes longer intellectual property protection periods for the expensive class of drugs known as biologics.
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Will this be the catalyst for big pharmaceutical companies to get into the pot business?
This morning, a Senate committee checks in to see how the cuts to the so-called 340b program, which allows hospitals to buy drugs at a discount, are impacting hospitals and patients. Critics say there’s little evidence that hospitals used the savings to help patients. Click the audio player above to hear the full story.
The FDA plans to unveil a website today naming pharmaceutical companies that have blocked the development of generic drugs by failing to provide samples to competitors. This public posting is part of FDA Commissioner Scott Gottlieb’s larger crackdown to, as he says, “end the shenanigans” by brand name drug companies. Click the audio player above […]